BFM
BCLI

Boothbay Fund Management’s BRAINSTORM CELL THERAPUTC BCLI Stock Holding History

Boothbay Fund Management’s Portfolio BCLI Stock Details BCLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-1,273
Closed -$39.3K – 1735
2023
Q2 		$39.3K Hold
1,273
– – ﹤0.01% 1689
2023
Q1 		$63K Hold
1,273
– – ﹤0.01% 2002
2022
Q4 		$31.3K Hold
1,273
– – ﹤0.01% 1905
2022
Q3 		$84K Sell
1,273
-585
-31% -$29.3K ﹤0.01% 2070
2022
Q2 		$77K Sell
1,858
-88
-5% -$3.96K ﹤0.01% 2026
2022
Q1 		$98K Hold
1,946
– – ﹤0.01% 2105
2021
Q4 		$117K Hold
1,946
– – ﹤0.01% 1680
2021
Q3 		$96K Sell
1,946
-243
-11% -$12.8K ﹤0.01% 1804
2021
Q2 		$125K Hold
2,189
– – ﹤0.01% 1693
2021
Q1 		$126K Buy
+2,189
New +$165K ﹤0.01% 1450

Other funds holding BCLI

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
LWM
Liberty Wealth Management Oakland, California $800M AUM 20.44% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
GS
GTS Securities New York $2.83B AUM 21.76% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
AHB
Abner Herrman & Brock Jersey City, New Jersey $1.05B AUM 42.66% 1-Year Est. Return
RJA
Raymond James & Associates St Petersburg, Florida $164B AUM 33.91% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return

Boothbay Fund Management's BCLI Position: Q3 2023 in Review

Boothbay Fund Management sold out of BRAINSTORM CELL THERAPUTC (BCLI) in Q3 2023, closing a stake of 1,273 shares — an estimated $39.3K sold.

Boothbay Fund Management first reported a position in BCLI in Q1 2021 and held it in 10 quarters. The position peaked at $126K in Q1 2021. 53 funds tracked by Wall St. Rank hold BCLI as of Q3 2023.

  • Boothbay Fund Management reported no remaining BRAINSTORM CELL THERAPUTC position as of Q3 2023 after selling out during the quarter.
  • Boothbay Fund Management sold 1,273 BRAINSTORM CELL THERAPUTC shares in Q3 2023, an estimated $39.3K.
  • Boothbay Fund Management first reported a position in BRAINSTORM CELL THERAPUTC in Q1 2021 and held it in 10 quarters.
  • Boothbay Fund Management's BRAINSTORM CELL THERAPUTC position peaked at $126K in Q1 2021.
  • 53 funds tracked by Wall St. Rank held BRAINSTORM CELL THERAPUTC as of Q3 2023.

Based on Boothbay Fund Management's 13F filing for Q3 2023, filed 14 Nov 2023.